Ads

You May Also Like

INmune Bio Initiates Phase I Clinical Trial of INB03

Clinical trial of novel innate immune system checkpoint inhibitor targeting myeloid derived suppressor cell ...

Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage ...

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...